Loading...
Nascent Biotech, Inc.
NBIO•PNK
HealthcareBiotechnology
$0.001
$-0.00(-12.50%)
Nascent Biotech, Inc. (NBIO) Stock Overview
Explore Nascent Biotech, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Revenue Growth
0.00%
Profit Growth
$-0.01
↑ 25.47%
EPS Growth
$-0.01
↑ 43.22%
Operating Margin
-44648637.44%
↓ 3.44%
ROE
358.30%
↑ 25.47%
Dividend Yield
0.00%
Analyst Recommendations data is not available for NBIOAnalyst Recommendations details for NBIO are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Company Profile
Nascent Biotech, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a drug to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as epithelial cancers, including lung, breast, colon, brain, and pancreas cancer. In addition, the company is developing MultiPharm, a proprietary technology platform for cancer therapy, as well as diabetes, autoimmunity, and transplantation. Nascent Biotech, Inc. is based in Vero Beach, Florida.
CEO
Mr. Sean Carrick
Headquarters
623 17th Street, Vero Beach, FL
Founded
2009